Biotronik has today announced the approval of two new indications for the Orsiro Mission drug-eluting stent (DES):
- One-month dual antiplatelet therapy (DAPT) for high bleeding risk (HBR) patients: Allows practitioners to offer personalised, shorter DAPT durations to their patients at high risk of bleeding events, in accordance with the most recent guidelines.
- Calcified lesions: Allows practitioners to target more complex lesions with moderate or severe calcification.
These new indications follow the company’s recent global regulatory approval of the Orsiro Mission DES for an increased maximum allowed diameter (MAD) post-dilation (Ø2.25–3mm, MAD: 4mm, Ø3.5–4mm, MAD: 5mm).
